Bladder Cancer
Kidney Cancer
EAU Edu Platform on Prostate Cancer
Home
Articles
Article of the Month
Editorial
Videos
Webcasts
Education
Online curriculum
E-courses
ESOU Online
Webinars
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorial
Videos
Webcasts
Education
Terug
Online curriculum
E-courses
ESOU Online
Webinars
Guidelines
Events
Upcoming event
ESU-ESUI Masterclass on Prostate biopsy
Home
/
ASCO GU22
/
Page 2
Back
Tag:
ASCO GU22
PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
View